Pharmascience Inc. contributes to the Montreal Heart Institute's COLchicine Cardiovascular Outcome Trial (COLCOT), a landmark study to benefit cardiovascular patients and the healthcare system

MONTREAL, Nov. 16, 2019 /PRNewswire/ - The Montreal Heart Institute (MHI) announced earlier today the results of its COLchicine Cardiovascular Outcomes Trial (COLCOT). This landmark study compared the effect of colchicine in the prevention of ischemic cardiovascular events in patients...

from PR Newswire: https://ift.tt/2rKaqv9